Personalized Hemodynamic Management Targeting Preoperative Baseline Cardiac Index in High-risk Patients Having Major Abdominal Surgery: the International Multicenter Randomized PELICAN Trial

Status: Recruiting
Location: See all (11) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Postoperative mortality within 30 days after surgery is around 2% in patients having major noncardiac surgery in Europe and the USA. In fact, if the first 30 days after surgery were considered a disease, it would be the third leading cause of death globally. Postoperative deaths are a consequence of postoperative organ injury and complications - including acute myocardial injury, acute kidney injury, and severe infectious complications. To avoid postoperative deaths, it is thus crucial to reduce postoperative organ injury and complications. To reduce postoperative organ injury and complications, modifiable risk factors need to be addressed. These modifiable risk factors for postoperative organ injury include low blood flow states and intraoperative hypotension. Optimizing blood flow (i.e., cardiac index) during surgery may thus be effective in reducing postoperative organ injury and complications. However, the optimal hemodynamic treatment strategy for high-risk surgical patients remains unclear. Cardiac index varies substantially between individuals. However, current intraoperative hemodynamic treatment strategies mainly aim to maximize cardiac index instead of using personalized cardiac index targets for each individual patient. A single-center pilot trial suggests that using individualized cardiac index targets during surgery may reduce postoperative organ injury and complications compared to routine hemodynamic management. However, large robust trials investigating the effect of personalized hemodynamic management targeting preoperative baseline cardiac index on postoperative complications are missing. The investigators, therefore, propose a multicenter randomized trial to test the hypothesis that personalized intraoperative hemodynamic management targeting preoperative baseline cardiac index reduces the incidence of a composite outcome of acute kidney injury, acute myocardial injury, non-fatal cardiac arrest, severe infectious complications, and death within 7 days after surgery compared to routine hemodynamic management in high-risk patients having elective major abdominal surgery.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ Consenting patients ≥45 years scheduled for elective major abdominal surgery (involving visceral organs) under general anesthesia that is expected to last ≥90 minutes AND presence of ≥1 of the following high-risk criteria:

• exercise tolerance \<4 metabolic equivalents as defined by the guidelines of the American College of Cardiology/American Heart Association

• renal impairment (serum creatinine ≥1.3 mg dL-1 or estimated glomerular filtration rate \<90 mL min-1 (1.73 m2)-1 within the last 6 months

• coronary artery disease

• chronic heart failure (New York Heart Association Functional Classification ≥II)

• valvular heart disease (moderate or severe)

• history of stroke

• peripheral arterial occlusive disease (any stage)

• chronic obstructive pulmonary disease (any stage) or pulmonary fibrosis (any stage)

• diabetes mellitus requiring oral hypoglycemic agent or insulin

• immunodeficiency due to a disease (e.g., HIV, leukemia, multiple myeloma) or therapy (e.g., immunosuppressants, chemotherapy, radiation, steroids \[above Cushing threshold\])

• liver cirrhosis (any Child-Pugh class)

• body mass index ≥30 kg m-2

• history of smoking within two years of surgery

• age ≥65 years

• expected surgery duration ≥180 minutes

• B-type natriuretic peptide (BNP) \>80 ng/L or N-terminal B-type natriuretic peptide (NT-proBNP) \>200 ng/L within the last 6 months

Locations
Other Locations
Austria
Medical University of Graz
RECRUITING
Graz
Denmark
Hvidovre Hospital
RECRUITING
Copenhagen
Rigshospitalet
RECRUITING
Copenhagen
University Medical Center Copenhagen Bispebjerg and Frederiksberg
RECRUITING
Copenhagen
Germany
University Hospital RWTH Aachen
NOT_YET_RECRUITING
Aachen
University Hospital Düsseldorf
RECRUITING
Düsseldorf
University Medical Center Hamburg
RECRUITING
Hamburg
University Medical Center Schleswig Holstein, Lübeck
RECRUITING
Lübeck
University Hospital Marburg
RECRUITING
Marburg
LMU Munich
RECRUITING
Munich
Spain
Clínica Universidad de Navarra
RECRUITING
Pamplona
Contact Information
Primary
Bernd Saugel, M.D.
b.saugel@uke.de
004940741052415
Backup
Moritz Flick, M.D.
m.flick@uke.de
004940741052415
Time Frame
Start Date: 2023-10-08
Estimated Completion Date: 2025-12
Participants
Target number of participants: 1128
Treatments
No_intervention: Routine hemodynamic management (control)
In patients assigned to routine hemodynamic management, hemodynamic management will performed as per anesthesiologist preference. Cardiac index monitoring will be will measured using the Baxter Starling Fluid Management System (Baxter, Deerfield, IL, USA). The attending anesthesiologist will be blinded to cardiac index measurements. Cardiac index monitoring can be unblinded upon request. Mean arterial blood pressure will be maintained above 65 mmHg.
Experimental: Personalized hemodynamic management (intervention)
In patients assigned to personalized hemodynamic management, intraoperative cardiac index will be maintained at least at the preoperative baseline cardiac index using a predefined treatment algorithm.~Preoperative baseline cardiac index will be determined with the patient being awake and resting in supine position using the Starling Fluid Management System (Baxter, Deerfield, IL, USA) (usually at least one day before surgery). We will define the individual preoperative baseline cardiac index as the average value over a 5 min period at rest (minimum cardiac index threshold: 2.2 L min-1 m-2).~Mean arterial blood pressure will be maintained above 65 mmHg. The study intervention will start at the beginning of surgery and will end at the end of surgery.
Related Therapeutic Areas
Sponsors
Leads: Universitätsklinikum Hamburg-Eppendorf

This content was sourced from clinicaltrials.gov